{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Positive Predictive Value"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"False Negative Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Concordance between results of plasma genotyping and tumor genotyping, among patients with tissue available for standard genotyping","groups":[{"description":"Participants who enrolled to the study and had plasma genotyping","id":"OG000","title":"Participants With Plasma Genotyping"}],"paramType":"NUMBER","populationDescription":"35 of the 42 participants with plasma genotyping results also had tumor genotyping results available, so PPV and false negative rate could be assessed in these 35 participants.","reportingStatus":"POSTED","timeFrame":"PPV and False Negative Rate can be assessed when plasma and tissue results are available for each patient; average plasma result turnaround time was 4 days, versus average of 20 days for tissue result turnaround time.","title":"Positive Predictive Value (PPV) And False Negative Rate Of Plasma Genotyping","type":"SECONDARY","unitOfMeasure":"percentage"}